Concurrent Resolution Directing PEHP Regarding Pain Medication

Removed the directive requiring the Public Employees' Benefit and Insurance Program to include non-opioid alternatives in its drug formulary.

Removed the mandate prohibiting more restrictive cost-sharing or prior authorization for non-opioid medications compared to opioids.

Deleted the provision authorizing $150,000 in funding to implement the resolution.

Updated document headers, dates, and line numbering while retaining the introductory 'Whereas' clauses.

Added a requirement to include at least one clinically appropriate non-opioid alternative for each opioid prescription drug in the formulary.

Added a prohibition on placing more restrictive cost-sharing, prior authorization, or step therapy requirements on non-opioid drugs compared to opioid drugs.

Added a requirement to implement the resolution within a $150,000 appropriation, with a provision to request additional funds if costs exceed this amount.

Extended the effective date of the plan year requirement from 2027 to explicitly include the 2027 plan year in the directive.

Extended the line range of the amendment to include the new funding and requirement provisions.

The effective date for the new coverage requirements was explicitly set to begin with the 2027 plan year.

The legislative directive was restructured to clearly separate the mandate to include non-opioid alternatives in the drug formulary from the rules regarding cost-sharing and utilization limits.

Added a specific effective date of the 2027 plan year for the new requirements to take effect.

Added a requirement to implement the resolution within an appropriation of $150,000, with a provision to request additional funds if costs exceed this limit.

Updated the House Sponsor's name from 'LONG TITLE' to 'Raymond P. Ward' and added 'Enrolled Copy' headers.